These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 29309244)

  • 21. Topical treatment of pityriasis rubra pilaris with calcipotriol.
    Van de Kerkhof PC; Steijlen PM
    Br J Dermatol; 1994 May; 130(5):675-8. PubMed ID: 7515639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pityriasis rubra pilaris: treatment with biologics - a new promising therapy?
    Ivanova K; Itin P; Haeusermann P
    Dermatology; 2012; 224(2):120-5. PubMed ID: 22508269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of Biologics in Pityriasis Rubra Pilaris Refractory to First-Line Systemic Therapy: A Systematic Review [Formula: see text].
    Naidoo A; Sibbald C; Fleming PJ; Piguet V
    J Cutan Med Surg; 2020; 24(1):73-78. PubMed ID: 31691587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Photoaggravated pityriasis rubra pilaris.
    Evangelou G; Murdoch SR; Palamaras I; Rhodes LE
    Photodermatol Photoimmunol Photomed; 2005 Oct; 21(5):272-4. PubMed ID: 16149942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pityriasis rubra pilaris: evolution of challenges in promising treatment options.
    Sehgal VN; Srivastava G; Verma P
    Skinmed; 2012; 10(1):18-23. PubMed ID: 22324172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute juvenile pityriasis rubra pilaris: a case report after mononucleosis infection.
    Betto P; Vassilopoulou A; Colombari R; Veller-Fornasa C
    G Ital Dermatol Venereol; 2008 Aug; 143(4):271-3. PubMed ID: 18833084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type III juvenile pityriasis rubra pilaris: a successful treatment with infliximab.
    Ruzzetti M; Saraceno R; Carboni I; Papoutsaki M; Chimenti S
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):117-8. PubMed ID: 18181990
    [No Abstract]   [Full Text] [Related]  

  • 28. Pityriasis Rubra Pilar and hypothyroidism.
    Franzotti AM; Avelar JC; Cardoso TA; Pires MC; Vidigal Mdo R
    An Bras Dermatol; 2014; 89(3):497-500. PubMed ID: 24937828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris.
    Bonomo L; Levitt JO
    Cutis; 2018 May; 101(5):367-369. PubMed ID: 29894526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of refractory pityriasis rubra pilaris with oral alitretinoin: case report.
    Molin S; Ruzicka T
    Br J Dermatol; 2010 Jul; 163(1):221-3. PubMed ID: 20346022
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of pityriasis rubra pilaris type I: a systematic review.
    Engelmann C; Elsner P; Miguel D
    Eur J Dermatol; 2019 Oct; 29(5):524-537. PubMed ID: 31789274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bath-PUVA as a treatment for Pityriasis rubra pilaris provoked by ultraviolet B.
    Kaskel P; Grundmann-Kollmann M; Schiller PI; Krähn G; Pillekamp H; Peter RU; Kerscher M
    Br J Dermatol; 1999 Apr; 140(4):769-70. PubMed ID: 10233350
    [No Abstract]   [Full Text] [Related]  

  • 33. Successful Treatment of Refractory Pityriasis Rubra Pilaris With Secukinumab.
    Schuster D; Pfister-Wartha A; Bruckner-Tuderman L; Schempp CM
    JAMA Dermatol; 2016 Nov; 152(11):1278-1280. PubMed ID: 27706476
    [No Abstract]   [Full Text] [Related]  

  • 34. [Diagnostic and therapeutic difficultes in pityriasis rubra pilaris--case report].
    Wcisło-Dziadecka D; Brzezińska-Wcisło L; Krauze E; Lis-Swiety A
    Pol Merkur Lekarski; 2005 Nov; 19(113):667-70. PubMed ID: 16498808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful response of refractory type I adult-onset pityriasis rubra pilaris with ustekinumab and acitretin combination therapy.
    Byekova Y; Sami N
    J Dermatol; 2015 Aug; 42(8):830-1. PubMed ID: 25982628
    [No Abstract]   [Full Text] [Related]  

  • 36. Effectiveness of infliximab in pityriasis rubra pilaris is associated with pro-inflammatory cytokine inhibition.
    Adnot-Desanlis L; Antonicelli F; Tabary T; Bernard P; Reguiaï Z
    Dermatology; 2013; 226(1):41-6. PubMed ID: 23548788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biologics for pityriasis rubra pilaris treatment: A review of the literature.
    Napolitano M; Abeni D; Didona B
    J Am Acad Dermatol; 2018 Aug; 79(2):353-359.e11. PubMed ID: 29609014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pityriasis rubra pilaris and HIV infection.
    Blauvelt A; Nahass GT; Pardo RJ; Kerdel FA
    J Am Acad Dermatol; 1991 May; 24(5 Pt 1):703-5. PubMed ID: 1869640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Refractory pityriasis rubra pilaris treated with etanercept, adalimumab, or ustekinumab: A retrospective investigation.
    Maloney NJ; Hisaw LD; Worswick S
    Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 29034547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pityriasis rubra pilaris. Further observations of systemic retinoid therapy.
    Borok M; Lowe NJ
    J Am Acad Dermatol; 1990 May; 22(5 Pt 1):792-5. PubMed ID: 2347965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.